
Company Information and Disclosure Statement

Section One: Issuers' Annual Disclosure Obligations for the For the Period Ended December 31, 2015

Discovery Minerals Ltd.
OTCPK: DSCR



OTC Pink Basic Disclosure Guidelines

1) Name of the issuer and its predecessors (if any):

Exact Company Name: Discovery Minerals LTD. (hereinafter referred to as "we", "us", or "our" or "the Issuer").
Name used by predecessor entities in the past five years: Dhanoa Minerals, Ltd. until 8/2012

2) Address of the issuer's principal executive offices:

Company Headquarters
13428 Maxella Avenue, Suite 294, Marina del Rey, California 90292 Phone: 310-961-4654
Email: info@discoverholdingscorp.com
Website: www.discoveryholdingscorp.com
IR Contact: None

3) Security Information

Trading Symbol: DSCR
CUSIP Number: 25470V109
Total shares authorized (5,000,000,000) Five Billion: Common: (4,986,999,994) Four Billion Nine Hundred Eighty Six Million Nine Hundred and Ninety Nine Thousand Nine Hundred and Ninety Four shares (as of 9/30/2015).
Preferred: (13,000,006) Thirteen Million and Six shares designated to three classes (as of 09/30/2015).
Par or Stated Value: Common: $0.00001 and Preferred stock: $0.0001(as of 09/30/2015).
Total shares outstanding: 3,821,645,833(as of 09/30/2015).
Common Stock Outstanding: 3,821,413,081 (as of 09/30/2015).
Restricted Common Stock: 712,066,753 (as of 09/30/2015).
Preferred Stock Outstanding: 232,752 Preferred C (as of 9/30/2015).
Transfer Agent:
Pacific Stock Transfer Company
6725 Via Austi Parkway, Suite 300, Las Vegas, NV 89119 Tel: (571) 485-9998
Registered Under Exchange Act: Yes
Regulatory Authority: Security Exchange Commission (SEC)
List any restrictions on the transfer of security: None
Describe any trading suspension orders issued by the SEC in the past 12 months: No

4) Issuance History:

On January 13, 2014, 170,000,000 shares were issued to a non affiliated third party as a result of a debt assignment on September 25th, 2013 and subsequent conversion of $1700 from a convertible promissory note dated January 23rd, 2012. The partial assignment of this debt has a conversion price of $0.00001. The shares were issued pursuant to the exemption from registration provided by Section 4(1) of the Securities Act of 1933. The shares were not registered or qualified in any jurisdiction. The shares were issued free of restrictive legend as the holding period of Rule 144 had been satisfied.

On February 11, 2014, 50,000,000 shares were issued to a non affiliate third party as a result of a debt assignment on November 25th, 2013 and subsequent conversion of $500 from a convertible promissory note dated January 23rd, 2012. The partial assignment of this debt has a conversion price of $0.00001. The shares were issued pursuant to the exemption from registration provided by Section 4(1) of the Securities Act of 1933. The shares were not registered or qualified in any jurisdiction. The shares were issued free of restrictive legend as the holding period of Rule 144 had been satisfied.

On February 24, 2014, 50,000,000 shares were issued to a non affiliate third party as a result of a debt assignment January 16th, 2014 and subsequent conversion of $500 from a convertible promissory note dated January 23rd, 2012. The partial assignment of this debt has a conversion price of $0.00001. The shares were issued pursuant to the exemption from registration provided by Section 4(1) of the Securities Act of 1933. The shares were not registered or qualified in any jurisdiction. The shares were issued free of restrictive legend as the holding period of Rule 144 had been satisfied.

On March 10, 2014, 50,000,000 shares were issued to a non affiliate third party as a result of a debt assignment January 15th, 2014 and subsequent conversion of $500 from a convertible promissory note dated January 23rd, 2012. The partial assignment of this debt has a conversion price of $0.00001. The shares were issued pursuant to the exemption from registration provided by Section 4(1) of the Securities Act of 1933. The shares were not registered or qualified in any jurisdiction. The shares were issued free of restrictive legend as the holding period of Rule 144 had been satisfied.

On April 17, 2014, 24,500,000 restricted common shares were issued to previous and existing directors for services amounting to $67,000.

On April 17, 2014, 10,000,000 restricted common shares were issued pursuant to a mining property option agreement amounting to $16,000.

On October 2, 2014, 50,000,000 shares were issued to a non affiliate third party as a result of a debt assignment January 16th, 2014 and subsequent conversion of $500 from a convertible promissory note dated January 23rd, 2012. The partial assignment of this debt has a conversion price of $0.00001. The shares were issued pursuant to the exemption from registration provided by Section 4(1) of the Securities Act of 1933. The shares were not registered or qualified in any jurisdiction. The shares were issued free of restrictive legend as the holding period of Rule 144 had been satisfied.

November 12, 2014, 30,000,000 shares were issued to a non affiliate third party as a result of a debt assignment November 4th, 2014 and subsequent conversion of $300 from a convertible promissory note dated January 23rd, 2012. The partial assignment of this debt has a conversion price of $0.00001. The shares were issued pursuant to the exemption from registration provided by Section 4(1) of the Securities Act of 1933. The shares were not registered or qualified in any jurisdiction. The shares were issued free of restrictive legend as the holding period of Rule 144 had been satisfied.

On November 21, 2014, 211,195,173 restricted common shares were issued in lieu of accrued services and joint venture costs.

On December 4, 2014, 30,000,000 restricted common shares were issued pursuant to a public relations and communications service agreement.

On December 29, 2014, 200,000,000 shares were issued to a non affiliate third part as a result of a debt assignment and subsequent conversion of $13,495 of the outstanding principal amount as evidenced by the Company's obligations to the note holder.

On February9, 2015, 153,000,000 shares were issued to the Chief Executive Officer in exchange for certain debts owed from the company.

On March 12, 2015, 250,000,000 shares were issued to a non affiliate third part as a result of a debt assignment and subsequent conversion of $25,000 of the outstanding principal amount as evidenced by the Company's obligations to the note holder.

On June 19, 2015, 600,000,000 shares were issued to the Chief Executive Officer in exchange for certain debts owed from the company.

On June 25, 2015, 270,000,000 shares were issued to a non affiliate third part as a result of a debt assignment and subsequent conversion of $27,000 of the outstanding principal amount as evidenced by the Company's obligations to the note holder.

On June 30, 2015, 375,000,000 shares were issued to a non affiliate third part as a result of a debt assignment and subsequent conversion of $37,500 of the outstanding principal amount as evidenced by the Company's obligations to the note holder.

5) Financial Statements

Discovery Minerals Ltd.

BALANCE SHEET

Period Ended December 31, 2015 and September 30, 2015

	December 31, 2015	September 31, 2015
ASSETS		
Current Assets		
Cash	$ 357	$ 460
Due from related party	1,000	1,000
TOTAL CURRENT ASSETS	1,357	1,460
TOTAL ASSETS	$ 1,357	$ 1,460
LIABILITIES AND STOCKHOLDERS' DEFICIT		
Current Liabilities		
Accounts payable and accrued expenses	$ 2,429	$ 1,429
Notes payable	140,025	133,990
Notes payable-related parties	3,527	2,714
TOTAL LIABILITIES	$ 145,981	$ 138,133
Stockholders' Deficit		
Preferred stock, Class A,B,C		
13,000,006 shares authorized, $.0001 par value, 232,752 Class C shares issued and outstanding at December 31, 2015	23	23
Common stock		
4,986,999,994 shares authorized, $0.00001 par value, 3,821,413,081 shares issued and outstanding at December 31, 2015 and September 30, 2015	40,714	40,714
Additional paid in capital	11,548,563	11,548,563
Accumulated Defecit	$ (11,733,924)	$ (11,725,973)
TOTAL STOCKHOLDERS' DEFICIT	(144,624)	(136,673)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	$ 1,357	$ 1,460

See accompanying accountant's compilation report.

Discovery Minerals Ltd.
STATEMENTS OF OPERATIONS
For The Three Months Ended December 31, 2015 and 2014

	December 31, 2015	December 31, 2014
REVENUES	**$** -	$ -
EXPENSES		
General and administrative	6,931	52,095
TOTAL OPERATING EXPENSES	6,931	52,095
OTHER INCOME		
Forgiveness of debt	-	7,500
Interest expense	(660)	(626)
TOTAL OTHER INCOME (EXPENSES)	(660)	6,874
NET INCOME (LOSS)	**$** (7,591)	$ (45,221)
EARNINGS PER SHARE	**$** (0.00)	$ (0.00)
WEIGHTED AVERAGE SHARES OUTSTANDING	3,821,413,081	2,300,329,019
BASIC AND DILUTED		

Discovery Minerals Ltd.

(A Development Stage Company)

STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT)

For the Year ended Septemebr 30, 2015 and the three month period ended December 31, 2015

	Common Stock		Preferred Stock				
	Shares	Amount	Shares	Amount	Additional Paid in Capital	Accumulated Deficit	Total
Balance, September 30, 2014	**1,657,217,908**	**$ 19,072**	**232,752**	**$ 23**	**$ 11,099,336**	**$ (11,664,585)**	**$ 546,154**
Common stock issued for debt conversion	280,000,000	2,800	-	-	11,495	-	14,295
Common stock issued for services	211,195,173	2,112	-	-	401,462	-	403,574
Common stock issued for debt conversion	250,000,000	2,500	-	-	22,500	-	25,000
Common stock issued for services	153,000,000	1,530	-	-	13,770	-	15,300
Common stock issued for debt conversion	645,000,000	6,450	-	-	-	-	6,450
Common stock issued for services	625,000,000	6,250	-	-	-	-	6,250
Net loss for the year ended September 30, 2015	-	-	-	-	-	(61,387)	(61,387)
Balance September 30, 2015	**3,821,413,081**	**$ 40,714**	**232,752**	**$ 23**	**$ 11,548,563**	**$ (11,725,972)**	**$ 955,636**
Net loss for the three months ended December 31,2015	-	-	-	-	-	$ (7,591)	(7,591)
Balance December 31, 2015	**3,821,413,081**	**$ 40,714**	**232,752**	**$ 23**	**$ 11,548,563**	**$ (11,733,563)**	**$ 948,045**

See accompanying accountant's compilation report.

Discovery Minerals Ltd.

STATEMENTS OF CASH FLOWS

For The Three Months Period Ended December 31, 2015 and 2014

	December 30,	
	2015	**2014**
CASH FLOWS FROM OPERATING ACTIVITIES		
Net income (loss) from operation	$ (7,951)	$ (45,221)
Adjustments to reconcile net income (loss) to net cash used by operating activities:		
Forgiveness of debt	-	7,500
Accrued Interest	660	-
Due from related party	-	1,000
Increase (decrease) in:		
Accounts payable and accrued expenses	1,000	15,992
NET CASH PROVIDED (USED) BY OPERATING ACTIVITIES	$ (6,291)	$ (417,013)
CASH FLOWS FROM INVESTING ACTIVITIES		
Purchase of property, plant and equipment	$ -	$ -

NET CASH USED BY INVESTING ACTIVITIES	$ -	$ -
CASH FLOWS FROM FINANCING ACTIVITIES		
Increase (decrease) in notes payable	6,188	9,520
Proceeds from sale of stock	-	-
Contribution of capital	-	-
NET CASH PROVIDED BY FINANCING ACTIVITIES	$ 6,188	$ 417,868
NET CHANGE IN CASH	(103)	855
CASH AT BEGINNING OF PERIOD	460	103
CASH AT END OF PERIOD	**$** 357	$ 958
SUPPLEMENTAL DISCLOSURE		
Income tax	$ -	$ -
Interest paid	$ -	$ 2,404
Consulting services	$ -	$ 48,000
	$ -	$ 67,000

See accompanying accountant's compilation report.

DISCOVERY MINERALS LTD.
Notes to Consolidated Financial Statements
December 31, 2015

Note 1 – Organization, Nature of Operations and Summary of Significant Accounting Policies

Organization and Business

Discovery Minerals Ltd., (OTC PINKSHEETS: DSCR.PK) is an acquisition and development company that targets natural resource properties through its wholly owned subsidiaries. These projects have previously fallen within two categories of natural products, precious metals mining and industrial hemp cultivation and processing. However, Discovery's future interests and activities will be focused on the marketing and distribution of Migranade, a homeopathic therapy for migraine headache sufferers, and the development of several other homeopathic treatments for common human ailments in conjunction with Doctor Charles Hensley. Dr. Hensley is best known for his groundbreaking treatment for the common cold, Zicam, released to the market in the late 1990s. Discovery has an agreement in place to secure all the technology underlying Migranade and the other treatments developed by Dr Hensley.
In addition, the Company is pursuing clean tech and alternative energy investments to be integrated into these business channels.

Use of Estimates

The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts of revenues and expense during the period. Actual results could differ from those estimates.

Fair Value of Financial Instruments

The carrying amount of the Company's cash and loans approximate their estimated fair values due to the short-term nature of those financial instruments.

Cash and cash equivalents

The Company considers all highly liquid investments purchased with original maturities of three months or less to be cash equivalents.

Income Taxes

Income taxes are accounted for in accordance with the provisions of FASB ASC Topic No. 740 - *Income Taxes*. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amounts expected to be realized.

The Company has a net operating loss carry forward of approximately $11,733,563 expiring between 2025 and 2033.

Stock-Based Compensation

Stock based compensation is accounted for under FASB ASC Topic No. 718 – *Compensation – Stock Compensation*. The guidance requires recognition in the financial statements of the cost of employee services received in exchange for an award of equity instruments over the period the employee is required to perform the services in exchange for the award (presumptively the vesting period). The guidance also requires measurement of the cost of employee services received in exchange for an award based on the grant-date fair value of the award. The Company accounts for non-employee share-based awards in accordance with guidance related to equity instruments that are issued to other than employees for acquisition, or in conjunction with selling, goods or services.

Basic and Diluted Net Loss per Common Share

Basic and diluted net loss per share calculations are presented in accordance with FASB ASC Topic No. 260 – *Earnings per Share*, and are calculated on the basis of the weighted average number of common shares outstanding during the period. Diluted net loss per share calculations include the dilutive effect of common stock equivalents in years with net income. Basic and diluted loss per share is the same due to the absence of common stock equivalents.

Recent Accounting Pronouncements

The Company does not expect the adoption of any other recently issued accounting pronouncements to have a significant effect on its consolidated financial position or results of operations.

Note 2 - Going Concern

As reflected in the accompanying consolidated financial statements, the Company has an accumulated deficit of $11,733,563 and negative working capital of $145,625 as of December 31, 2015. This raises substantial doubt about the Company's ability to continue as a going concern. The Company's ability to continue as a going concern is dependent on its ability to raise additional capital and implement its business plan. The consolidated financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.

Management believes that actions presently being taken to obtain additional funding and implement its strategic plans provide the opportunity for the Company to continue as a going concern.

Note 3 – Common Stock

During the year ended September 30, 2015, the Company issued 2,164,195,173 shares of common stock for converting debt amounting to $61,387.

During the year ended September 30, 2015, the Company issued 778,000,000 shares to officers and directors for services amounting to $21,550 and 211,195,173 shares issued to consultants in lieu of accrued services and joint venture costs amounting to $403,574.

Note 4 – Forgiveness of Debt

During the year ended September 30, 2015, several notes payable were forgiven totaling $7,500.00.

Note 5 - Subsequent Events

In accordance with ASC 855-10, management has evaluated subsequent events through the date the financial statements were issued and have determined that no subsequent events occurred.

6) Describe the Issuer's Business, Products and Services

A. Discovery Minerals Ltd., is an acquisition and development company that targets natural resource properties through its wholly owned subsidiaries. These projects have previously fallen within two categories of natural products, precious metals mining and industrial hemp cultivation and processing. However, Discovery's future interests and activities will be focused on the marketing and distribution of Migranade, a homeopathic therapy for migraine headache sufferers, and the development of several other homeopathic treatments for common human ailments in conjunction with Doctor Charles Hensley. Dr. Hensley is best known for his groundbreaking treatment for the common cold, Zicam, released to the market in the late 1990s. Discovery has an agreement in place to secure all the technology underlying Migranade and the other treatments developed by Dr. Hensley. In addition, the Company is pursuing clean tech and alternative energy investments to be integrated into these business channels.

B. Date and State (or Jurisdiction) of Incorporation: The Company was originally incorporated in 2005, in the state of Nevada.

C. The issuer's primary and secondary SIC codes: Primary Code: 1000 - Metal Mining. Secondary Code: 100

D. The issuer's fiscal year end date: September 30

E. **Principal products or services, and their markets:** Discovery Minerals Ltd., is an acquisition and development company that targets natural resource properties through its wholly owned subsidiaries. These projects have previously fallen within two categories of natural products, precious metals mining and industrial hemp cultivation and processing. However, Discovery's future interests and activities will be focused on the marketing and distribution of Migranade, a homeopathic therapy for migraine headache sufferers, and the development of several other homeopathic treatments for common human ailments in conjunction with Doctor Charles Hensley. Dr. Hensley is best known for his groundbreaking treatment for the common cold, Zicam, released to the market in the late 1990s. Discovery has an agreement in place to secure all the technology underlying Migranade and the other treatments developed by Dr. Hensley. In addition, the Company is pursuing clean tech and alternative energy investments to be integrated into these business channels.
F.

The Company entered into a Joint Venture Agreement with AB AGRO TECHNOLOGIES of which Discovery has committed to issue 33,500,000 shares of its common restricted stock in exchange for a 50% split of Net revenue from the resale and processing of the cultivated Industrial Hemp seed and fiber.

Subsequently, Discovery entered into a Joint Venture Agreement with VPR Group Inc., in conjunction with AB AGRO to pursue the research, development and processing of extracting Cannibidiol Oil (CBD Oil) from Industrial Hemp. VPR Group will also facilitate the processing of the remaining Hemp Bio-Mass to be utilized for Biofuel. The Company has committed to exchange like kind equity in each company of 4.99%.

7) Describe the Issuer's Facilities

The Company leases offices at 13428 Maxella Avenue, Suite#294, Marina del Rey, CA 90292. The lease is held by the Company's Chief Executive Officer and he does not charge the Company for use of any space.

8) Officers, Directors, and Control Person

A. Names of Officers, Directors, and Control Persons:

Russell Smith, CEO and Director
Person Named above owns 754,000,000 shares of Common stock.

William McNerney, Director
Person Named above owns 34,500,000 shares of Common stock.

Michael Silver, Director
Person Named above owns 5,000,000 shares of Common stock.

B. Legal/Disciplinary History. Please identify whether any of the foregoing persons have, in the last five years, been the subject of:

1. A conviction in a criminal proceeding or named as a defendant in a pending criminal proceeding (excluding traffic violations and other minor offenses); None

2. The entry of an order, judgment, or decree, not subsequently reversed, suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person's involvement in any type of business, securities, commodities, or banking activities; None

3. A finding or judgment by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission, the Commodity Futures Trading Commission, or a state securities regulator of a violation of federal or state securities or commodities law, which finding or judgment has not been reversed, suspended, or vacated; None

4. The entry of an order by a self-regulatory organization that permanently or temporarily barred, suspended or otherwise limited such person's involvement in any type of business or securities activities; None

C. Beneficial Shareholders. provide a list of the name, address and shareholdings or the percentage of shares owned by all persons beneficially owning more than ten percent (10%) of any class of the issuer's equity securities. if any of the beneficial shareholders are corporate shareholders, provide the name and address of the person(s) owning or controlling such corporate shareholders and the residents agents of the corporate shareholders.
N/A

9) Third Party Providers

Legal Counsel:
John E. Dolkart, Jr., Esq.
1750 Kettner Blvd., Ste 416, San Diego, CA 92101
Tel: (702) 275-2181 www.dolkartlaw.com

Naccarato & Associates
18881 Von Karman Avenue, Suite 1440
Irvine, CA 92612
(949) 851-9261

Investor Relations Consultant
None

Public Relations Services
Pacific Equity Alliance LLC
Zachary R. Logan / Drew S. Philips
858.886.7237
info@pacificequityusa.com

10) Issuer Certification

The issuer shall include certifications but the chief executive officer and chief financial officer of the issuer (or any other person with different title, but having the same responsibilities).

I, Russell Smith, certify that:

I have reviewed this Annual Disclosure Statement of Discovery Minerals Ltd.;

1. ***Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and***

2. ***Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.***

Date: 2/3/2015
Russell Smith
/S/ Russell Smith
Title: CEO and President